فريقنا

Dr. Mike Zack is a pioneering physician-scientist and entrepreneur at the forefront of AI-driven precision medicine and multi-omics technologies. With over a decade of specialized experience, he co-founded and currently leads PGxAI, an advanced pharmacogenetics platform leveraging artificial intelligence to optimize drug therapies individually based on comprehensive biological data. His distinguished career includes over 150 peer-reviewed publications, positioning him in the top 1% of globally cited scientists (Elsevier), with an H-index of 48 and over 50K citations. His research has significantly impacted pharmacogenomics, personalized medicine, and AI-driven healthcare, shaping international clinical practices and therapeutic standards. At PGxAI, Dr. Zack spearheaded the launch of innovative AI models integrating genetic, proteomic, transcriptomic, metabolomic, and clinical data. This multi-dimensional approach enables unprecedented precision in medication selection and dosage, improving therapeutic effectiveness and patient safety. Under his leadership, PGxAI rapidly evolved from concept to a thriving enterprise, establishing strategic partnerships with leading global technology and healthcare organizations, including InterSystems, Google, Amazon, and Microsoft. His vision has driven practical applications that enhance clinical decision-making and reduce adverse drug reactions in real-world settings. As a recognized global healthcare innovator, Dr. Zack frequently engages with executives, investors, policymakers, and academia, advocating for accelerated adoption of AI and personalized medicine solutions worldwide.

Allan Gobbs is a Venture Capitalist and Deeptech Entrepreneur. He is a Co-Founder and Managing Partner at ATEM Capital, a New York-based Life Sciences venture firm (www.atemcap.com). His experience includes a $760 million strategic partnership with Domain Associates, one of the oldest US biotech venture groups, where he made 11 high-profile private investments (5 companies listed on NASDAQ, including Atea Pharmaceuticals which demonstrated 30x cash-on-cash return at IPO valuation, 3 companies sold, including Tobira Therapeutics, which was sold at an unprecedented premium of 19x to its current market cap to Allergan). Allan is a Founder of GATELEAD — Global Advanced Technology Entrepreneurship and Leadership School. GATELEAD applies a unique personalized competency-based approach combined with project-focused learning and empowers teams driving corporate innovations or building their own breakthrough enterprises in Life Sciences, Medtech/Diagnostics & Healthtech. Before that Mr. Gobbs was a Vice President at Barclays Capital focusing on Energy & Utilities, Telecoms and High Tech sectors. Mr. Gobbs started off his investment banking career at Dresdner Kleinwort, where he advised on a number of M&A and capital markets transactions worth over $20 billion. Board Memberships include: Marinus (NASDAQ: MRNS), Tobira (NASDAQ: TBRA, sold to Allergan), Neothetics (NASDAQ: NEOT, sold), OcuNexus, Adastra, NovaDigm, Atea (NASDAQ: AVIR) and Revision Optics (observer), Syndax (NASDAQ: SNDX) (observer), Miramar Labs (observer, sold). Mr. Gobbs is an official member of the Forbes Business Council, a member of the Private Directors Association (PDA) (previously he was also a member of the National Association of Corporate Directors) and a member of the Review Committee of the National Cancer Institute at NIH.

With a rich background in tech development, Alex has made significant strides at Intel Corporation, where he has served for over 14 years. His role as Product Manager and Architect has been crucial in developing the Intel® Single Event API and managing the post-silicon development of Graphics Drivers for MacOS, in collaboration with Apple. His earlier contributions at Intel include improving performance and usability with the VTune Amplifier XE and leading architectural developments in the Graphics Performance Analyzers. Before Intel, Alex was instrumental in developing surveillance products at Speclab, showcasing his diverse skill set in software and hardware architecture. His innovative approach and leadership in tech development mark him as a key asset to our team.

Russ Biagio Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science) and past chairman of the Bioengineering Department at Stanford University. His primary research interests are in the application of computing (AI, data science and informatics) to problems relevant to medicine. He is particularly interested in methods for understanding drug action at molecular, cellular, organism and population levels. His lab studies how human genetic variation impacts drug response (e.g., http://www.pharmgkb.org/). Other work focuses on the analysis of biological molecules to understand the actions, interactions and adverse events of drugs (e.g., http://helix.stanford.edu/). He helps lead an FDA-supported Center of Excellence in Regulatory Science & Innovation. Dr. Altman holds an AB from Harvard College, and an MD from Stanford Medical School, and a PhD in Medical Information Sciences from Stanford. He received the U.S. Presidential Early Career Award for Scientists and Engineers and a National Science Foundation CAREER Award. He is a fellow of the American College of Physicians (ACP), the American College of Medical Informatics (ACMI), the American Institute of Medical and Biological Engineering (AIMBE), and the American Association for the Advancement of Science (AAAS). He is a member of the National Academy of Medicine. He is a past-president, founding board member, and a fellow of the International Society for Computational Biology (ISCB), and a past-president of the American Society for Clinical Pharmacology & Therapeutics (ASCPT). He has chaired the Science Board advising the FDA commissioner, and has served on the NIH Director’s Advisory Committee, and as cochair of the IOM Drug Forum. He is an organizer of the annual Pacific Symposium on Biocomputing, and a founder of Personalis (NASDAQ: PSNL). Dr. Altman is board certified in Internal Medicine and in Clinical Informatics. He received the Stanford Medical School graduate teaching award in 2000 and 2020, and the mentorship award in 2014. He is the founding editor of the Annual Reviews of Biomedical Data Science, and hosts a podcast entitled “The Future of Everything.”

John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, with additional faculty roles in the Channing Division of Network Medicine and the Dana-Farber Cancer Institute. Trained as a theoretical physicist (PhD, UCLA), he joined the Human Genome Project in 1992 and held positions at the Salk Institute, Stanford, and The Institute for Genomic Research before arriving at Harvard in 2005. A leader in systems and network biology, he has published 350 + peer-reviewed papers cited over 103 000 times, co-founded the precision-medicine platform Genospace, and was recognized as a White House Open Science Champion of Change (2013) and elected to the National Academy of Medicine (2022). At PGxAI, Dr Quackenbush advises on multi-omics integration, reproducibility standards, and the clinical translation of AI-driven pharmacogenomic insights.

David Blumenthal is a nationally recognized physician and health policy expert with a career spanning academic medicine, government leadership, and healthcare innovation. He served as the National Coordinator for Health Information Technology under President Obama from 2009 to 2011, where he led one of the largest public infrastructure initiatives in U.S. history—overseeing the implementation of the HITECH Act’s "meaningful use" incentives to digitize American healthcare. Dr. Blumenthal earned his BA, MD, and MPP from Harvard University, completed his residency at Massachusetts General Hospital, and held academic roles across Harvard Medical School, the Kennedy School of Government, and the Harvard School of Public Health. Over four decades, he has combined front-line medical practice with influential policy work. He was Chief Health Advisor to Governor Michael Dukakis during his presidential campaign (1987–88) and later to President Obama’s 2008 campaign. In academia, he served as Director of the Institute for Health Policy at MGH and National Correspondent for the New England Journal of Medicine, contributing thought leadership on health systems reform. His contributions earned him the title of Modern Healthcare’s Most Influential Physician Executive in 2010. Blumenthal is widely respected for bridging clinical insight with visionary policy design in U.S. healthcare.

Emily received her Ph.D in Molecular Pathology from UCSD in 2002 investigating specificity of metalloproteinases in breast cancer metastasis using phage display libraries. As a postdoctoral fellow she began studying molecular mechanism of tumor suppressor genes and breast cancer metastasis using shotgun proteomics. In 2009, she joined Stony Brook School of Medicine and then joined Columbia University School of Medicine in 2013 as an independent investigator and as the director of proteomics shared resource to support mass spectrometry-based analysis. She has extensive publications on applying proteomics technology to study basic biology and translational biomarker discovery using patient samples. In 2018, she joined Thermo Fisher as the Sr. director of the Precision Medicine Science Center in Cambridge MA.

Dr. Terry Robins is a distinguished leader in the design and execution of global clinical trials, clinical laboratory operations, and the commercialization of innovative diagnostic technologies. With a PhD in Molecular Biology from the University of California, Berkeley, he brings over two decades of senior leadership experience at industry frontrunners such as Abbott, Alere, and Quest Diagnostics. During his tenure as Senior Director of Clinical Affairs, Infectious Disease at Abbott, Dr. Robins directed large-scale international trials and was instrumental in guiding advanced diagnostic solutions from concept to market. Prior to Abbott, he served as Global Director of Scientific Affairs and Biomarker R&D at Quest Diagnostics, spearheading the development and integration of novel biomarkers across multiple disease areas. His track record also includes driving high-impact R&D initiatives as Vice President at Pathway Diagnostics. A graduate of the prestigious I-Corps @ NIH Program, Dr. Robins has a proven history of translating cutting-edge science into real-world clinical and commercial success. At PGxAI, he provides strategic advisory in harnessing AI-driven precision medicine, ensuring that next-generation multi-omics platforms seamlessly reach patients and clinicians for improved outcomes worldwide.

Nisha Talagala, CEO and founder of AIClub.World, is passionate about fostering AI literacy among K-12 students and individuals globally. With a wealth of experience in introducing Artificial Intelligence to learners of all levels, Nisha has played a pivotal role in advancing the field. As a co-founder of ParallelM, a pioneering force in MLOps acquired by DataRobot, Nisha has been a driving force in operational machine learning. Her leadership extends to organizing the USENIX Operational ML Conference, the premier event bridging industry and academia on production AI/ML. With over 20 years of expertise spanning enterprise software development, distributed systems, and technical strategy, Nisha’s contributions are underscored by a PhD from UC Berkeley, 75 patents, over 25 research publications, and frequent speaking engagements at industry and academic events. Additionally, she contributes as a writer for Forbes and other esteemed publications.

Bruce Broussard is an American businessman with 30+ years of public company experience in CEO and CFO roles, delivering exceptional results and value for stakeholders across numerous environments, from private to public companies to startups and mid-size to Fortune 50 companies, all with varying levels of financial structures. ​ ​ A seasoned veteran in the healthcare industry, Bruce has held a wide range of executive leadership positions in publicly traded and private organizations in healthcare sectors of oncology, pharmaceuticals, assisted living/senior housing, home care, physician practice management, surgical centers, and dental networks.​ ​ Bruce is the former President and Chief Executive Officer of Humana Inc., one of the nation’s leading public healthcare companies focused on helping improve the quality of life of millions of people in the United States through its insurance and healthcare services. ​ ​ Prior to leading Humana for 12 years, Bruce was Chief Executive Officer of McKesson Specialty/US Oncology, Inc. US Oncology was purchased by McKesson in December 2010. At US Oncology, Bruce served in numerous senior executive roles, including Chief Financial Officer, President, Chief Executive Officer, and Chairman of the Board.​ ​ Bruce is a member of the HP Inc. Board and the HealthQuest Advisory Board, and plays a leadership role in The Business Council, a key business advocacy organization. He previously served on the Boards of KeyBank and US Physical Therapy, in addition to extending his leadership in numerous advocacy organizations including the Business Roundtable, the American Heart Association CEO Roundtable, the World Economic Forum Health Governors Board, and AHIP. ​ Additionally, Bruce currently serves on the Humana Foundation Board and is Chair of the Board of Directors of the Trust for the National Mall, a nonprofit philanthropic partner of the National Park Service dedicated to restoring and preserving the National Mall.

Roni Zeiger is a physician and product leader with more than two decades of experience at the intersection of healthcare, technology, and community. He brings clinical credibility and product rigor to organizations of all sizes—from mission‑driven nonprofits and startups to global technology companies—consistently delivering patient‑centered products and strategies. A seasoned healthcare innovator, Roni has held leadership roles across consumer health, patient communities, digital health, and responsible AI. He served for 17 years as an urgent care physician at Santa Clara Valley Medical Center, grounding his product work in the realities of frontline care. Roni is the former Head of Health Strategy at Meta (2019–2023), where he partnered across product, policy, and research to advance health initiatives at scale. Earlier, he served as Chief Health Strategist at Google (2006–2012), helping shape the company’s approach to health and to make health information more useful and accessible. In 2012, Roni co‑founded Smart Patients, an online community where patients and caregivers learn from each other. As CEO through 2019, he led the team in building a trusted, patient‑centered platform and partnering with leading healthcare organizations. Today, Roni advises teams on product strategy, product management, and AI strategy. His advisory portfolio currently includes Added Health, Moneta Health, Noora Health, HERA Digital Health, and Streetwyze (since November 2024). Prior to his current advisory work, he served as Director of Product Development at GirlTrek (January–October 2024), bringing his passion for community‑centered technology to a health movement engaging more than one million Black women.

David A. Moser is a dynamic commercial leader at the intersection of digital health, diagnostics, and precision medicine. With a track record of launching new ventures and building high-performing sales organizations, David has propelled revenue growth for cutting-edge companies like GeneDx, imaware, and Deciphex. Throughout his career, David has excelled at bridging innovation with real-world market needs—negotiating complex sales agreements, orchestrating strategic partnerships, and guiding early-stage tech transformations from concept to commercial success. His deep expertise spans genomics, digital pathology, and at-home testing solutions, enabling him to deliver scalable go-to-market strategies and impactful collaborations with hospitals, CROs, and leading biotech firms. Passionate about advancing healthcare through actionable diagnostics and AI-driven insights, David’s leadership style centers on forging genuine relationships and delivering measurable results. His ability to connect the dots between diverse stakeholders—clinicians, innovators, and payers—embodies his commitment to making top-tier diagnostic and genomic solutions accessible to patients worldwide.

Dr. Dave Vigerust is a nationally recognized scientist-entrepreneur who has spent more than two decades turning breakthrough discoveries into market-shaping health-tech products. Currently Chief Scientific & Strategy Officer at Spectrum Solutions and Adjunct Faculty at Vanderbilt University School of Medicine, he has led FDA-cleared diagnostic programs, directed multi-omics clinical trials, and secured multiple patents spanning infectious disease, oncology, neuro-inflammation, and forensic genomics. A TEDx presenter and recipient of numerous industry awards, Dr. Vigerust combines deep laboratory expertise with seasoned commercial acumen—guiding strategy, capital formation, and go-to-market execution for venture-backed life-science companies. His 50+ peer-reviewed publications and keynote addresses for organizations such as ISBER and the Alliance for Health Reform underscore his commitment to translating precision medicine from bench to bedside. At PGxAI, Dave advises on product-market fit, regulatory pathways, and strategic partnerships, helping accelerate our mission of delivering AI-driven pharmacogenomics to every clinician and patient worldwide.